Norges Bank Takes $124.69 Million Position in Ralliant Corporation $RAL

Norges Bank acquired a new stake in shares of Ralliant Corporation (NYSE:RAL) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 2,449,160 shares of the company’s stock, valued at approximately $124,687,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Ralliant by 10.7% during the third quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock worth $637,995,000 after buying an additional 1,415,327 shares during the period. Viking Global Investors LP purchased a new position in shares of Ralliant in the 2nd quarter valued at $257,200,000. State Street Corp purchased a new position in shares of Ralliant in the 2nd quarter valued at $213,096,000. Invesco Ltd. raised its position in shares of Ralliant by 90.1% in the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after acquiring an additional 1,835,128 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Ralliant by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 1,872,647 shares of the company’s stock worth $95,357,000 after acquiring an additional 17,893 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on RAL shares. Royal Bank Of Canada raised their price objective on Ralliant from $47.00 to $64.00 and gave the company a “sector perform” rating in a research report on Wednesday, May 13th. Zacks Research upgraded shares of Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Barclays increased their price target on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Oppenheimer raised their price target on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Finally, Citigroup lifted their price objective on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Ralliant currently has an average rating of “Hold” and a consensus target price of $64.50.

Ralliant Stock Down 0.7%

Ralliant stock opened at $62.25 on Friday. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. The stock has a market capitalization of $6.97 billion and a price-to-earnings ratio of -5.69. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $63.31. The business has a fifty day moving average price of $50.40 and a 200-day moving average price of $49.12.

Ralliant (NYSE:RAL) last announced its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million for the quarter. The firm’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio is -1.83%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.